Cost-effectiveness of Cladribine Tablets in Human Patients with RRMS
A study analyzed the cost-effectiveness of cladribine tablets for active relapsing-remitting multiple sclerosis (RRMS) against 12 recommended disease-modifying therapies (DMTs). It found cladribine tablets to be both less costly and more effective when compared to several medications, including ocrelizumab and dimethyl fumarate, suggesting significant cost savings and delayed disease progression in various scenarios.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Demonstrated in people
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Positive
Why it matters
These findings highlight cladribine tablets as a potentially more cost-efficient option for treating RRMS, which is important for healthcare decision-making and resource allocation, especially for the National Health Service.
What this does not prove
The study's main limitation is the uncertainty associated with the estimated effects, particularly regarding the large credible intervals related to disability progression over six months.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Other
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-10-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Yes
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- patients with active relapsing-remitting multiple sclerosis
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceCost-effectiveness of cladribine tablets for the treatment of active relapsing-remitting multiple sclerosis in the United Kingdom. ↗DOI: 10.1080/03007995.2026.2734647
Supporting passages (16)
study phaseThis analysis assessed the cost-effectiveness of cladribine tablets from the perspective of the National Health Service in patients with active relapsing-remitting multiple sclerosis (RRMS).
study designMETHODS: A cohort-based Markov model with 11 health states (10 disability states plus death) was developed.
subjectsThis analysis assessed the cost-effectiveness of cladribine tablets from the perspective of the National Health Service in patients with active relapsing-remitting multiple sclerosis (RRMS).
speciesThis analysis assessed the cost-effectiveness of cladribine tablets from the perspective of the National Health Service in patients with active relapsing-remitting multiple sclerosis (RRMS).
regulatory approvalIn March 2024, UK regulators expanded approval of cladribine tablets to all adults with active relapsing MS, not just the most severe cases.
relevant ms typesOBJECTIVE: The approved indication of cladribine tablets has recently been expanded in the United Kingdom for the treatment of all adult patients with active relapsing multiple sclerosis.
publication datePublication date: 2026-10-22
interventionless costly and more effective) vs ponesimod, ocrelizumab, ofatumumab, dimethyl fumarate, diroximel fumarate, and teriflunomide in pairwise comparisons.
comparatorIn addition to best supportive care without disease-modifying therapy (DMT), 12 recommended DMTs were included as comparators to cladribine tablets over a 50-year horizon.
primary endpointThis analysis assessed the cost-effectiveness of cladribine tablets from the perspective of the National Health Service in patients with active relapsing-remitting multiple sclerosis (RRMS).
findingsless costly and more effective) vs ponesimod, ocrelizumab, ofatumumab, dimethyl fumarate, diroximel fumarate, and teriflunomide in pairwise comparisons.
limitationsSensitivity analyses supported the base case that cladribine tablets are cost-effective vs ponesimod, ofatumumab, and ocrelizumab; the main source of uncertainty was related to the large credible intervals associated with 6-month CDP.
populationThis analysis assessed the cost-effectiveness of cladribine tablets from the perspective of the National Health Service in patients with active relapsing-remitting multiple sclerosis (RRMS).
outcomeCONCLUSIONS: This economic analysis demonstrated that cladribine tablets are a cost-effective treatment option for patients with active RRMS.
human efficacyCONCLUSIONS: This economic analysis demonstrated that cladribine tablets are a cost-effective treatment option for patients with active RRMS.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.